Alto Neuroscience pioneers drug development for cognitive impairment in schizophrenia, targeting biomarkers to enhance treatment precision and patient outcomes.
Amit Etkin, MD, PhD
Advertisement
Articles by Amit Etkin, MD, PhD
Etkin describes precision psychiatry data for MDD presented at the Society for Biological Psychiatry Annual Meeting.
Learn more about Alto Neuroscience's ALTO-300, in ongoing phase 2b trials as an adjunct treatment for major depressive disorder.
How can we enhance our understanding of the human brain?
Advertisement
Latest Updated Articles
Alto Neuroscience Presents Key Data, Study Findings on ALTO-300Published: December 26th 2024 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Symptoms Are Not Necessarily Signs of Illness: Rethinking Synchronicity in Psychiatry
2
Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders
3
Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder
4
Our Readers on the Need to be Nice to Our Pharmacists
5
